aortic stenosis clinical trials results

atorvastatin versus placebo
SALTIRE, 2005	atorvastatin 80mg daily versus placebo	patients with calcific aortic stenosis	double blind Follow-up duration: 25 mo (7-36)
ezetimibe+simvastatin versus placebo
SEAS, 2008 NCT00092677	simvastatin 40mg plus ezetimibe 10 mg daily versus placebo	patients with mild-tomoderate, asymptomatic aortic stenosis	double blind Follow-up duration: 52.2 mo Europe
rosuvastatin versus placebo
ASTRONOMER, 2010 ISRCTN 32424163	rosuvastatin 40 mg daily versus placebo	asymptomatic patients with mild to moderate aortic stenosis and no clinical indications for cholesterol lowering	double blind Follow-up duration: 3.5 y
transcatheter aortic valve implantation versus standard therapy
PARTNER, 2010 NCT00530894	transcatheter aortic-valve implantation (TAVI)with Edwards SAPIEN Transcatheter Heart Valve versus standard therapy	patients with severe aortic stenosis considered not to be suitable candidates for surgery	open Follow-up duration: 1.6 y (at least1 year) USA
transcatheter aortic valve implantation versus surgical valve replacement
PARTNER cohort A, 2011 NCT00530894	percutaneous valve implantation (Sapien device) versus surgical valve replacement	high risk, symptomatic patients with severe aortic stenosis	US, Canada, Germany